[HTML][HTML] Efficacy and long-term safety of a dengue vaccine in regions of endemic disease
…, HI Hj Muhammad Ismail, H Reynales… - … England Journal of …, 2015 - Mass Medical Soc
Background A candidate tetravalent dengue vaccine is being assessed in three clinical
trials involving more than 35,000 children between the ages of 2 and 16 years in Asian–Pacific …
trials involving more than 35,000 children between the ages of 2 and 16 years in Asian–Pacific …
[HTML][HTML] Efficacy of a tetravalent dengue vaccine in children in Latin America
…, R Cunha, C Deseda, H Reynales… - … England Journal of …, 2015 - Mass Medical Soc
Background In light of the increasing rate of dengue infections throughout the world despite
vector-control measures, several dengue vaccine candidates are in development. Methods …
vector-control measures, several dengue vaccine candidates are in development. Methods …
[HTML][HTML] Efficacy of a tetravalent dengue vaccine in healthy children and adolescents
S Biswal, H Reynales, X Saez-Llorens… - … England Journal of …, 2019 - Mass Medical Soc
Background Dengue, a mosquito-borne viral disease, was designated a World Health
Organization top 10 threat to global health in 2019. Methods We present primary efficacy data …
Organization top 10 threat to global health in 2019. Methods We present primary efficacy data …
Three-year efficacy and safety of Takeda's dengue vaccine candidate (TAK-003)
…, S Biswal, X Sáez-Llorens, H Reynales… - Clinical Infectious …, 2022 - academic.oup.com
Background Takeda’s live attenuated tetravalent dengue vaccine candidate (TAK-003) is
under evaluation in a long-term clinical trial across 8 dengue-endemic countries. Previously, …
under evaluation in a long-term clinical trial across 8 dengue-endemic countries. Previously, …
Efficacy of a tetravalent dengue vaccine in healthy children aged 4–16 years: a randomised, placebo-controlled, phase 3 trial
…, C Sirivichayakul, EJ Rodriguez-Arenales, H Reynales… - The Lancet, 2020 - thelancet.com
Background A substantial unmet need remains for safe and effective vaccines against dengue
virus disease, particularly for individuals who are dengue-naive and those younger than 9 …
virus disease, particularly for individuals who are dengue-naive and those younger than 9 …
Efficacy of the adjuvanted subunit protein COVID-19 vaccine, SCB-2019: a phase 2 and 3 multicentre, double-blind, randomised, placebo-controlled trial
…, L Brochado, EA Hernández, H Reynales… - The Lancet, 2022 - thelancet.com
Background A range of safe and effective vaccines against SARS CoV 2 are needed to
address the COVID 19 pandemic. We aimed to assess the safety and efficacy of the COVID-19 …
address the COVID 19 pandemic. We aimed to assess the safety and efficacy of the COVID-19 …
Comparison of the safety and immunogenicity of an MF59®-adjuvanted with a non-adjuvanted seasonal influenza vaccine in elderly subjects
SE Frey, MR Aplasca-De Los Reyes, H Reynales… - Vaccine, 2014 - Elsevier
Aim Adjuvanted influenza vaccines can overcome the poor antibody response of conventional
non-adjuvanted vaccines in the elderly. We evaluated the immunogenicity, safety and …
non-adjuvanted vaccines in the elderly. We evaluated the immunogenicity, safety and …
Efficacy of a dengue vaccine candidate (TAK-003) in healthy children and adolescents 2 years after vaccination
…, MT Alera, H Velásquez, H Reynales… - The Journal of …, 2022 - academic.oup.com
Background Takeda’s dengue vaccine is under evaluation in an ongoing phase 3 efficacy
study; we present a 2-year update. Methods Children (20 099, 4–16 years old) were …
study; we present a 2-year update. Methods Children (20 099, 4–16 years old) were …
Prevention of influenza during mismatched seasons in older adults with an MF59-adjuvanted quadrivalent influenza vaccine: a randomised, controlled, multicentre …
J Beran, H Reynales, A Poder, YY Charles… - The Lancet Infectious …, 2021 - thelancet.com
Background The absolute degree of protection from influenza vaccines in older adults has
not been studied since 2001. This study aimed to show the clinical efficacy of an MF59-…
not been studied since 2001. This study aimed to show the clinical efficacy of an MF59-…
Tetravalent dengue vaccine reduces symptomatic and asymptomatic dengue virus infections in healthy children and adolescents aged 2–16 years in Asia and Latin …
…, P Pitisuttithum, H Reynales… - The Journal of …, 2016 - academic.oup.com
Background. Asymptomatic dengue virus–infected individuals are thought to play a major
role in dengue virus transmission. The efficacy of the recently approved quadrivalent CYD-…
role in dengue virus transmission. The efficacy of the recently approved quadrivalent CYD-…
